PARIS, FRANCE / ACCESSWIRE / October 20, 2023 / Abivax SA (Euronext Paris:FR0012333284:ABVX) (' Abivax ' or the ' Company '), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today the pricing of its initial public offering on the Nasdaq Global Market by way of a capital increase of 20,325,500 new ordinary shares (the ' New Shares '), consisting of a public offering of 18,699,460 ordinary shares in the form of American Depositary Shares (' ADSs '), each representing the right to receive one ordinary share, in the United States (the ' U.S.

法国巴黎/ACCESSWIRE/2023年10月20日/Abivax SA（Euronext PARIS:FR0012333284:ABVX）（'Abivax'或'公司'），一家临床阶段生物技术公司，专注于开发利用人体自然调节机制调节慢性炎症性疾病患者的免疫反应，今天宣布通过资本增加20325500股新普通股（“新股”）在纳斯达克全球市场首次公开发行的定价，其中包括以美国存款股形式公开发行18699460股普通股（'ADSs'），每个代表在美国获得一股普通股的权利（'U.S。

Offering ') and a concurrent offering of 1,626,040 ordinary shares in certain jurisdictions outside of the United States to certain investors (the ' European Private Placement ' and together with the U.S. Offering, the ' Global Offering '). The offering price was set at $11.60 per ADS in the U.S. Offering and a corresponding offering price of €10.9864 per ordinary share based on an exchange rate of €1.00 = $1.0559 as published by the European Central Bank on October 19, 2023.

提供”），并在美国以外的某些司法管辖区同时向某些投资者（``欧洲私募股权''以及美国发行的``全球发行''）提供1626040股普通股。根据欧洲中央银行于2023年10月19日发布的1.00欧元=1.0559美元的汇率，该发行价格设定为美国发行的每广告11.60美元，相应发行价格为每普通股10.9864欧元。

The aggregate gross proceeds are expected to be approximately $235.8 million, equivalent to approximately €223.3 million, before deduction of underwriting commissions and estimated expenses payable by the Company. The Global Offering is expected to close on October 24, 2023, subject to the satisfaction of customary closing conditions..

在扣除本公司应付的承保委员会和估计费用之前，所得总额预计约为2.358亿美元，相当于约2.233亿欧元。在满足习惯性关闭条件的前提下，预计全球产品将于2023年10月24日结束。。

All securities to be sold in the Global Offering will be offered by the Company. The ADSs have been approved for listing on the Nasdaq Global Market and are expected to begin trading on October 20, 2023 under the ticker symbol 'ABVX'. The Company's ordinary shares are listed on the regulated market of Euronext Paris (' Euronext Paris ') under the symbol 'ABVX'..

所有在全球发行中销售的证券将由公司提供。ADS已被批准在纳斯达克全球市场上市，预计将于2023年10月20日在票务符号“ABVX”下开始交易。该公司的普通股在Euronext Paris（'Euronext Paris'）的受监管市场上以符号'ABVX'列出。。

The ordinary shares underlying the ADSs sold in the Global Offering will be subject to an application for admission to trading on Euronext Paris (Compartment B) on the same trading line as the existing shares under the same ISIN code FR0012333284 and are expected to be admitted to trading on October 24, 2023..

在全球发行版中出售的ADSs所属的普通股将须根据同一ISIN代码FR0012333284在与现有股相同的交易线上申请进入Euronext Paris（B室）的交易，并预计将被录取2023年10月24日交易。。

Morgan Stanley and Leerink Partners are acting as joint global coordinators for the proposed Global Offering and joint bookrunners for the U.S. Offering. LifeSci Capital is acting as lead manager for the proposed U.S. Offering. Bryan, Garnier & Co is acting as European lead manager for the proposed European Private Placement (collectively, the ' Underwriters ')..

Morgan Stanley和Leerink合作伙伴是拟议的全球发行和美国发行的联合图书管理员的联合全球协调员。LifeSci Capital担任拟议美国产品的首席经理。Bryan，Garnier＆Co担任拟议的欧洲私募股权（统称为“承销商”）的欧洲首席经理。。

Namsen Capital is acting as Abivax's capital markets advisor.

Namsen Capital担任Abivax的资本市场顾问。

Pricing of the Global Offering and Discount

全球优惠和折扣定价

The offering price was set at $11.60 per ADS. The offering price per ADS corresponds to the offering price of €10.9864 per ordinary share based on the October 19, 2023 exchange rate of €1.00 = $1.0559.

发行价格定为每广告11.60美元。根据2023年10月19日的汇率1.00欧元=1.0559美元，每广告的发行价格相当于每普通股10.9864欧元的发行价格。

The public offering price per ordinary share in euros (€10.9864) is equal to the volume weighted-average price of the Company's ordinary shares on Euronext Paris over the last three (3) trading days preceding the start of the offering (i.e., 16th, 17th and 18th of October 2023), less a discount of 9.4%, and is determined by the Company in compliance with the 15th resolution of the Company's combined general shareholders' meeting held on June 5, 2023..

以欧元（10.9864欧元）计算的普通股公开发行价格等于本公司在Euronext Paris上的普通股在发行前最后三（3）个交易日（即2023年10月16日，17日和18日）的体积加权平均价格，折扣率为9.4%，并由公司根据2023年6月5日召开的公司合并股东大会第15号决议确定。。

Type of Offering

提供类型

The New Shares will be issued through a capital increase without shareholders' preferential subscription rights by way of a public offering excluding offerings referred to in Article L. 411-2 1° of the French Monetary and Financial Code ( Code monétaire et financier ) and under the provisions of Article L.225-136 of the French Commercial Code ( Code de commerce ) and pursuant to the fifteenth and nineteenth resolutions of the Company's combined general shareholders' meeting held on June 5, 2023..

新股份将通过资本增加发行，无股东优先订阅权，通过公开发行，不包括法国货币和金融法典（Code monétaireet Financer）第L.411-2条1°中提及的发行，以及根据法国商业法典（Code de commerce）第L.225-136条的规定并根据第十五条以及2023年6月5日举行的本公司联合股东大会第十九届决议。。

Option to Purchase Additional Shares

购买额外股份的选择

The Company has granted the Underwriters an option to purchase (the ' Option '), for a 30-day period (until November 20, 2023), up to 3,048,825 additional ADSs and/or ordinary shares, which represents 15% of the aggregate amount of New Shares to be issued in the Global Offering, at the same offering price..

本公司已授予承销商在30天内（至2023年11月20日）购买的选项（“期权”），最多3048825个额外的ADS和/或普通股，占总数的15%以相同的发行价格在全球发行的新股数量。。

Stabilization

稳定

In connection with the Global Offering, the Underwriters may over-allot the securities or effect transactions with a view to supporting, stabilizing, or maintaining the market price of the securities at a level higher than which might otherwise prevail in the open market. However, there is no assurance that the stabilizing manager will take any stabilization action and, if begun, may be ended at any time without prior notice.

关于全球发行，承销商可能过度分配证券或进行交易，以支持，稳定或维持证券的市场价格高于公开市场中可能占优势的水平。但是，不能保证稳定经理会采取任何稳定行动，如果开始，可以随时终止而无需事先通知。

Any stabilization action or over-allotment shall be carried out in accordance with all applicable rules and regulations and may be undertaken on the Nasdaq Global Market and/or Euronext Paris..

任何稳定行动或超额分配应按照所有适用的规则和法规进行，并可在纳斯达克全球市场和/或Euronext Paris进行。。

Dilution

稀释

Based on the issuance of 20,325,500 New Shares in the Global Offering (including ordinary shares in the form of ADSs), the number of ordinary shares held by the existing shareholders after the Global Offering would be 67.7% of the total number of ordinary shares (including ordinary shares in the form of ADSs) outstanding after the Global Offering.

根据全球发行20325500股新股（包括ADSs形式的普通股），全球发行后现有股东持有的普通股数量将占普通股总数的67.7%（包括ADSs形式的普通股）在全球发行后尚未发行。

If the Underwriters exercise their option to purchase 3,048,825 additional ADSs and/or ordinary shares in full, the number of ordinary shares held by the existing shareholders after the Global Offering would be 64.5% of the total number of ordinary shares (including ordinary shares in the form of ADSs) outstanding after the Global Offering..

如果承销商行使购买3048825个额外ADS和/或普通股的选择，全球发行后现有股东持有的普通股数量将占普通股总数（包括普通股）的64.5%。ADSs的形式）在全球发行后到期。。

Estimated Proceeds from the Global Offering - Reasons of the offering - Use of proceeds

全球发行的估计收益-发行原因-收益的使用

The gross proceeds of the sale of 20,325,500 New Shares, including ordinary shares in the form of ADSs, in the Global Offering is expected to be approximately $235.8 million (€223.3 million), assuming no exercise of the Underwriters' Option.

假设不行使承销商的期权，全球发行20325500股新股（包括ADSs形式的普通股）的总收益预计约为2.358亿美元（2.233亿欧元）。

The Company estimates that the net proceeds of the Global Offering will be approximately $212.2 million (€201.1 million), after deducting approximately $16.5 million (€15.6 million) in underwriting commissions and approximately $7.0 million (€6.6 million) in estimated offering expenses.

该公司估计，在承保委员会扣除约1650万美元（1560万欧元）和约700万美元（660万欧元）的估计发行费用后，全球发行的净收益将约为2.1220亿美元（2.011亿欧元）。

The Company expects to use the net proceeds from the Global Offering as follows (assuming an exchange rate of €1.00 = $1.0559, the exchange rate on October 19, 2023):

本公司预计将使用全球发行的净收益如下（假设汇率为1.00欧元=1.0559美元，即2023年10月19日的汇率）：

approximately €160.0 million ($168.9 million) to fund the development of obefazimod for UC;

大约1.6亿欧元（1.689亿美元）用于资助加州大学奥贝法齐莫德的开发；

approximately €14.0 million ($14.8 million) to fund the development of obefazimod for CD; and

大约1400万欧元（1480万美元）用于资助CD的obefazimod的开发；和

the remainder for working capital and for other general corporate purposes, including in the continued research to identify new compounds and the payment of maturities of existing debt agreements as they become due (mostly allocated to payments under the Kreos / Claret Financing (as defined below), and assuming that the Company will repay the Heights Financing (as defined below) through the issuance of new shares instead of making cash payments)..

其余用于营运资本和其他一般公司用途，包括继续研究确定新化合物和支付现有债务协议到期时的成熟度（主要分配给Kreos/Claret融资下的付款（定义如下），并假设公司将通过发行新股而不是支付现金来偿还Heights融资（定义如下）。。

The Company believes that the anticipated net proceeds from the Global Offering, together with its current cash and cash equivalents, will allow it to finance its operations through (i) the announcement of its top-line data from its Phase 3 ABTECT-1 and ABTECT-2 induction trials for UC and (ii) the announcement of its top-line data from its Phase 2a induction trial for CD..

本公司认为，全球发行的预期净收益及其当前现金和现金等价物将允许其通过（i）公布其第3阶段ABTECT-1和ABTECT-2的顶级数据为其运营提供资金。UC的诱导试验和（ii）公布其CD的2a期诱导试验的顶线数据。。

The Company believes that based on its current clinical plan and its anticipated net proceeds from the Global Offering, together with (a) its existing cash and cash equivalents of €114.4 million as of June 30, 2023, (b) the net proceeds of the August 2023 drawdown of the first tranches of the financing agreements entered into with entities affiliated with Kreos Capital (' KC ') and Claret European Growth Capital (the ' Kreos / Claret Financing ') and entities affiliated with Heights Capital Management (the ' Heights Financing '), collectively amounting to €27.2 million (net of repayments of all outstanding amounts that remained due under the prior two financing agreements entered into with KC and the OCEANE bonds), (c) the anticipated net proceeds from the drawdown of the second tranche of the Kreos / Claret Financing, amounting to €25 million (which is a portion of the total available drawdown of €65 million from the Kreos / Claret Financing and the Heights Financing) and (d) the expected Research Tax Credit (CIR) reimbursements would enable the Company to fund its operations through the fourth quarter of 2025.

本公司认为，根据其目前的临床计划及其预计的全球发行净收益，以及（a）截至2023年6月30日的现有现金和现金等价物11440万欧元，（b）2023年8月的净收益取消与Kreos Capital（'KC'）和Claret European Growth Capital（'Kreos/Claret financing'）附属实体和附属实体签订的第一批融资协议。高地资本管理（'Heights financing'），总计2720万欧元（根据与KC和大洋洲债券签订的前两项融资协议剩余的所有未偿还金额的偿还总额），（c）从撤回第二部分Kreos/克莱特融资，总计2500万欧元（这是Kreos/Claret融资和Heights融资总额6500万欧元可用拨款总额的一部分）和（d）预期的研究税收抵免（CIR）报销将使公司能够资助其运营到2025年第四季度。

Under these assumptions and based on its current clinical plan, the Company would have sufficient funds to finance its operations through (i) the announcement of its top-line data from the Phase 3 ABTECT-1 and ABTECT-2 induction trials for UC and (ii) the announcement of its top-line data from the Phase 2a induction trial for CD..

根据这些假设并根据其当前的临床计划，该公司将有足够的资金通过（i）公布其来自UC的3期ABTECT-1和ABTECT-2诱导试验的顶级数据以及（ii））公布其来自CD阶段2a诱导试验的顶级数据。。

If the Company further draws down on the third tranche of the Kreos / Claret Financing, amounting to €25 million and the second tranche of the Heights Financing amounting to €40 million, the Company expects to have sufficient funds to finance its operations through the first quarter of 2026. Under these assumptions and based on its current clinical plan, it would have sufficient funds to finance its operations through the announcement of its top-line data from the Phase 3 ABTECT maintenance trial for UC..

如果公司进一步减掉Kreos/Claret融资的第三部分，总额为2500万欧元，第二部分Heights融资总额为4000万欧元，公司预计将有足够的资金为其运营提供资金2026年第一季度。根据这些假设并根据其当前的临床计划，它将有足够的资金通过公布其来自UC的第3阶段ABTECT维护试验的顶级数据来资助其运营。。

Underwriting

承保

The Global Offering is subject to an underwriting agreement entered into on October 19, 2023. The underwriting agreement does not constitute a ' garantie de bonne fin ' within the meaning of Article L. 225-145 of the French Commercial Code ( Code de commerce ).

全球发行受2023年10月19日签订的承销协议约束。根据法国商业法（商业法）第225-145条的含义，承保协议不构成“garantie de bonne fin”。

Documentation

文档

The securities referred to in this press release will be offered only by means of a prospectus. When available, copies of the final prospectus relating to and describing the terms of the proposed Global Offering may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@morganstanley.com ; or Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext.

本新闻稿中提到的证券将仅通过IPO提供。如果有的话，可以从以下网站获得与拟议的全球发行条款有关并描述其条款的最终IPO副本：Morgan Stanley＆Co.LLC，注意：IPO部门，纽约州纽约市2楼180 Varick Street，邮编10014或通过电子邮件prospectus@morganstanley.com ; 或Leerink Partners LLC，注意：集团部门，53 State Street，40楼，波士顿，MA 02109，电话：（800）808-7525，分机。

6105, or by email at syndicate@leerink.com ..

6105，或者通过电子邮件syndicate@leerink.com ..

Application will be made to list the new ordinary shares to be issued pursuant to the Global Offering on Euronext Paris pursuant to a listing prospectus subject to an approval from the French Autorité des marchés financiers (' AMF ') and comprising (i) the 2023 Universal Registration Document ( Document d'Enregistrement Universel 2023 ) filed with the AMF on May 4, 2023 under number D.23-0394, as amended by a first amendment filed with the AMF on September 29, 2023 under number D.23-0394-A01, as completed by a second amendment to such 2023 Universal Registration Document, which will be filed with the AMF, and (ii) a Securities Note ( Note d'opération ), including a summary of the prospectus.

根据法国自动投资银行（AMF）批准的上市招股说明书，将根据Euronext Paris的全球发行情况列出新的普通股，并包括（i）2023年通用注册文件（文件d'Enregistrement Universel 2023）于2023年5月4日以d.23-0394编号向AMF提交，根据2023年9月29日提交给AMF的第一项修正案，编号为D.23-0394-A01，由2023年通用注册文件的第二项修正案完成，该文件将提交给AMF，以及（ii）证券说明（注释），包括IPO摘要。

Copies of the 2023 Universal Registration Document are available free of charge at the Company's head office located at 7-11 boulevard Haussmann, 75009 Paris, France, on the Company's website ( www.abivax.com ) and on the website of the AMF ( www.amf-france.org/ )..

2023通用注册文件的副本可在位于法国巴黎75009号豪斯曼大道7-11号的公司总部，公司网站（www.abivax.com）和AMF网站上免费获得（www.AMF-France.org/）。。

Risk Factors

风险因素

Investors should carefully consider the risks factors likely to affect the Company's business as described in Chapter 3 'Risk Factors' of the 2023 Universal Registration Document, in Chapter 5 of its first amendment and in Chapter 3 of its second amendment and in the risk factors section of the Company's registration statement on Form F-1 before marking an investment decision.

投资者应仔细考虑可能影响公司业务的风险因素，如2023年通用注册文件第3章“风险因素”，第一次修订第5章和第二次修订第3章以及风险因素部分所述。在做出投资决定之前，公司在F-1表格上的注册声明。

If any of these risks are realized, the Company's business, financial condition, operating results and prospects could be materially and adversely affected. In addition, other risks, not identified or considered significant by the Company, could have the same adverse effect and investors could lose all or part of their investment..

如果实现这些风险中的任何一项，公司的业务，财务状况，运营结果和前景可能会受到重大不利影响。此外，公司未发现或认为重大的其他风险可能会产生相同的不利影响，投资者可能会失去全部或部分投资。。

About Abivax

关于Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Based in France and the U.S., Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis..

Abivax是一家临床阶段的生物技术公司，专注于开发利用人体自然调节机制调节慢性炎症性疾病患者免疫反应的治疗药物。总部设在法国和美国的Abivax的主要候选药物obefazimod（ABX464）正处于治疗中度至重度活动性溃疡性结肠炎的3期临床试验中。。

Contacts:

联络：

Abivax Communications

Abivax通信

Regina Jehle

Regina针

regina.jehle@abivax.com

regina.jehle@abivax.com

+33 6 24 60 69 63

+33 6 24 60 69 63

Abivax Investor Relations

Abivax投资者关系

Patrick Malloy

帕特里克·马洛伊

patrick.malloy@abivax.com

patrick.malloy@abivax.com

+1 847 987 4878

+1 847 987 4878

Forward-Looking Statements

前瞻性声明

This press release contains certain forward-looking statements with respect to the Global Offering, including: the completion of the Global Offering, use of proceeds from the Global Offering, as well as statements regarding Abivax's clinical development plans, business and regulatory strategy, and anticipated future performance.

本新闻稿包含有关全球产品的某些前瞻性声明，包括：完成全球产品，使用全球产品收益，以及有关Abivax临床开发计划，业务和监管策略以及预期未来业绩的声明。

Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements.

尽管本公司认为其预期基于合理的假设，但这些前瞻性陈述存在许多风险和不确定性，这可能导致实际结果与前瞻性陈述中表达，暗示或预测的实际结果大不相同。

These risks and uncertainties include among other things, the uncertainties inherent in research and development, including related to progression of, and results from, its ongoing and planned clinical trials, including clinical trials for obefazimod, review and approvals by regulatory authorities, such as the FDA or the EMA, of its drug candidates and the Company's continued ability to raise capital to fund its development, including as part of the proposed Global Offering, the Company's ability to obtain, maintain, protect and enforce its intellectual property rights, as well as those discussed or identified in the Company's registration statement on Form F-1 filed with the U.S.

这些风险和不确定性包括研究和开发中固有的不确定性，包括与其正在进行和计划的临床试验的进展和结果相关的不确定性，包括obefazimod的临床试验，监管机构的审查和批准，如FDA或EMA，其候选药物和公司持续筹集资金以资助其发展的能力，包括作为拟议全球产品的一部分，公司获得，维护，保护和执行其知识产权的能力，以及在其中讨论或确定的能力。公司向美国提交的F-1型注册声明。

Securities and Exchange Commission and the Company's public filings with the AMF, in particular in the 2023 Universal Registration Document, as amended, for additional information in relation to such factors, risks and uncertainties..

证券交易委员会和公司与AMF的公开申请，特别是经修订的2023年通用注册文件，以获取有关这些因素，风险和不确定性的更多信息。。

Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in the Company in any country.

除适用法律要求外，本公司不承担更新或修改任何前瞻性信息或声明的任何义务。本新闻稿和此处包含的信息不构成出售或征求购买或订阅任何国家/地区公司股份的报价。

This press release has been prepared in both French and English. In the event of any differences between the two versions of the press release, the French language version shall supersede..

本新闻稿以法文和英文编写。如果新闻稿的两个版本之间存在任何差异，法文版本将取代。。

Disclaimers

免责声明

This press release does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of ordinary shares or ADSs in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售或征求购买报价的提议，也不构成在任何国家或管辖区销售普通股或ADS的任何销售，其中此类报价，征求或销售在注册之前是非法的或根据任何此类州或管辖区的证券法进行资格认证。。

The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.

在某些司法管辖区，本文件的分发可能受到当地法律的限制。拥有本文件的人必须告知自己并遵守任何此类潜在的当地限制。

A French listing prospectus comprising (i) the 2023 Universal Registration Document ( Document d'Enregistrement Universel 2023 ) filed with the AMF on May 4, 2023 under number D.23-0394, as amended by a first amendment filed with the AMF on September 29, 2023 under number D.23-0394-A01, as completed by a second amendment to such 2023 Universal Registration Document, which will be filed with the AMF, and (ii) a Securities Note ( Note d'opération ), including a summary of the prospectus, will be submitted to the approval by the AMF and will be published on the AMF's website at www.amf-france.org/ .

法国上市说明书，包括（i）2023年5月4日向AMF提交的2023年通用注册文件（文件d'Enregistrement Universel 2023），编号为d.23-0394，经AMF于9月29日提交的第一修正案修正2023年编号为d.23-0394-A01，由2023年通用注册文件的第二次修正案完成，将向AMF提交，以及（ii）证券笔记（注释说明），包括IPO摘要，将提交AMF批准，并将在AMF的网站上发布。www.AMF-france.org/。

Following the filing of the second amendment to the 2023 Universal Registration Document with the AMF, copies of Company's 2023 Universal Registration Document, as amended, will be available free of charge at the Company's head office located at 7-11 boulevard Haussmann, 75009 Paris, France..

在向AMF提交2023年通用注册文件的第二次修订后，经修订的公司2023年通用注册文件副本将在位于75009巴黎豪斯曼大道7-11号的公司总部免费提供。法国。。

European Economic Area

欧洲经济区

In relation to each Member State of the European Economic Area (each, a ' Relevant State '), no offer to the public of ordinary shares and ADSs may be made in that Relevant State other than:

对于欧洲经济区的每个成员国（每个成员国为“相关州”），除以下情况外，不得在该相关州向公众提供普通股和ADS的报价：

to any legal entity which is a qualified investor as defined under Article 2(e) of the Prospectus Regulation;

根据IPO条例第2（e）条定义的任何作为合格投资者的法人实体；

to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or

少于150名自然或法人（根据IPO说明书规定定义的合格投资者除外），但须获得代表事先同意以进行任何此类报价；或

in any other circumstances falling within Article 1(4) of the Prospectus Regulation,

在任何其他情况下，均属于IPO条例第1（4）条，

provided that no such offer of the securities shall require the Company or any of its representatives to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation.

但证券的此类报价不得要求本公司或其代表根据承销说明书条例第3条发布承销说明书，或根据承销说明书条例第23条补充承销说明书。

For the purposes of this provision, the expression an 'offer to the public' in relation to the securities in any Relevant State means the communication in any form and by any means presenting sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase any securities, and the expression ' Prospectus Regulation ' means Regulation (EU) 2017/1129 of June 14, 2017, as amended..

就本条而言，与任何有关州的证券有关的「向公众提供」一词，是指以任何形式进行通讯，并以任何方式提供有关报价条款及所提供证券的充分资料，以便投资者决定购买任何证券，“承销说明书条例”一词是指经修订的2017年6月14日第（EU）2017/1129号条例。。

France

法国

The securities have not been and will not be offered or sold to the public in the Republic of France, and no offering of this prospectus or any marketing materials relating to securities may be made available or distributed in any way that would constitute, directly or indirectly, an offer to the public in the Republic of France (except for public offerings defined in Article L.411-2 1° of the French Monetary and Financial Code ( Code monétaire et financier ))..

该证券尚未也不会在法国共和国向公众提供或出售，并且不得以任何直接或间接构成该证券的方式提供或分发本IPO或与证券有关的任何营销材料，向法国共和国公众提供的报价（法国货币和金融法典第L.411-2条规定的公开发行除外（代码monétaireet Financer））。。

The securities may only be offered or sold in France pursuant to Article L. 411-2 1° of the French Monetary and Financial Code ( Code monétaire et financier ) to qualified investors ( investisseurs qualifiés ) (as such term is defined in Article 2(e) of the Prospectus Regulation) acting for their own account, and in accordance with Articles L.

根据法国货币和金融法典（代码monétaireet Financer）第411-2条1°，证券只能在法国向合格投资者（investisseurs qualifiés）提供或销售（如本条款第2条所定义）（e）的IPO条例）为自己的账户行事，并按照第L条。

411-1, L. 411-2 and D. 411-2 to D.411-4 of the French Monetary and Financial Code ( Code monétaire et financier )..

法国货币和金融代码（代码monétaireet Financer）的411-1，L。411-2和D。411-2至D.411-4。。

This announcement is not an advertisement and not a prospectus within the meaning of the Prospectus Regulation.

本公告不是广告，也不是招股说明书法规含义内的IPO。

SOURCE: ABIVAX

来源：ABIVAX

View source version on accesswire.com:

在AccessWire.com上查看源版本：

https://www.accesswire.com/794963/abivax-announces-the-pricing-of-its-initial-public-offering-on-the-nasdaq-global-market

https://www.accesswire.com/794963/abivax-announces-the-pricing-of-its-initial-public-offering-on-the-nasdaq-global-market